Elanco, the animal health division of Eli Lilly and Company, announced the closing of its acquisition of the animal health business of Janssen Pharmaceutica NV – a Johnson & Johnson Company.
Elanco, the animal health division of Eli Lilly and Company, announced the closing of its acquisition of the animal health business of Janssen Pharmaceutica NV, a Johnson & Johnson Company. Elanco gained final approval from the European Commission last week (July 7).
The acquisition continues Elanco‘s growth in Europe, diversifying the food animal portfolio while complementing its companion animal business — including the launch of the company’s new Comfortis chewable flea tablet for dogs.
Janssen Animal Health‘s presence, pipeline and people will allow Elanco customers access to broader products and services. Terms of the deal were not disclosed.
Elanco president Jeff Simmons said: “The addition of a strong animal health team along with a number of highly respected brands will further strengthen Elanco’s mission of delivering greater value for our customers. Elanco continues to invest in and reinforce its commitment to animal health, creating unique growth opportunities at a time when many are consolidating.”
Products in the acquisition include:
- Surolan – for treatment of ear infections in dogs and cats,
- Flubenol – for nematodes in swine and poultry, and
- Vecoxan – for coccidial infections in calves and lambs.
Elanco will continue to deliver these highly respected brands in the manner customers have come to expect. The products will continue to be manufactured with the same high standards and quality practices, and the product ordering process will continue as is.